Preoperative levosimendan infusion in combined aortic valve and coronary bypass surgery

British Journal of Anaesthesia

Volumn 106, Issue 3, 2011, Pages 298-304

  Leppikangas, H ^a   Jrvela K ^a   Sisto, T ^a   Maaranen, P ^a   Virtanen, M ^a   Lehto, P ^a   Karlsson, S ^a   Koobi T ^a   Lindgren, L ^a  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

cardiovascular; coronary artery bypass; heart; inotropism; surgery

Indexed keywords

ADRENALIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE MB; DOBUTAMINE; DRUG METABOLITE; FLUORIDE PLUS VITAMIN; LEVOSIMENDAN; MILRINONE; N [4 (1,4,5,6 TETRAHYDRO 4 METHYL 6 OXO 3 PYRIDAZINYL)PHENYL]ACETAMIDE; NITROPRUSSIDE SODIUM; NORADRENALIN; OR 1855; UNCLASSIFIED DRUG;

ADD ON THERAPY; AGED; AORTA VALVE REPLACEMENT; ARTICLE; BOLUS INJECTION; CARDIOVASCULAR AUTOREGULATION; CLINICAL ARTICLE; CORONARY ARTERY BYPASS SURGERY; DIASTOLE; DOPPLER ECHOCARDIOGRAPHY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; FEMALE; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE WALL; HEART STROKE VOLUME; HEMODYNAMIC MONITORING; HIGH RISK PATIENT; HUMAN; IMPEDANCE CARDIOGRAPHY; MALE; POSTOPERATIVE PERIOD; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PULMONARY ARTERY CATHETER; RANDOMIZED CONTROLLED TRIAL; SURGICAL PATIENT; SYSTOLE; TISSUE DOPPLER IMAGING;

EID: 79951574278     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aeq402     Document Type: Article

References (29)

1. Mehta RH, Bruckman D, Das S, et al. Implications ofincreased left ventricular mass index on in-hospital outcomes in patients undergoing aortic valve surgery. J Thorac Cardiovasc Surg 2001; 122: 919-28
2. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 2004; 110: e340-437
3. Polonen P, Ruokonen E, Hippelainen M, Poyhonen M, Takala J. A prospective, randomized study of goal-oriented hemodynamic therapy in cardiac surgical patients. Anesth Analg 2000; 90: 1052-9 (Pubitemid 30253449)
4. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 1995; 27: 1859-66
5. Ukkonen H, Saraste M, Akkila J, et al. Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 2000; 68: 522-31
6. Follath F, Cleland JG, Just H, et al. Efficacy and safety of intrave-nous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002; 360: 196-202 (Pubitemid 34804646)
7. Tritapepe L, De Santis V, Vitale D, et al. Levosimendan pre-treatment improves outcomes in patients undergoing coronary artery bypass graft surgery. Br J Anaesth 2009; 102: 198-204
8. Nijhawan N, Nicolosi AC, Montgomery MW, Aggarwal A, Pagel PS, Warltier DC Levosimendan enhances cardiac performance after cardiopulmonary bypass: a prospective, randomized placebo-controlled trial. J Cardiovasc Pharmacol 1999; 34: 219-28 (Pubitemid 29350503)
9. Morelli A, De Castro S, Teboul JL, et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005; 31: 638-44 (Pubitemid 40684980)
10. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ. Pharmaco-kinetics of levosimendan and its metabolites during and after a 24-h continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 2002; 40: 465-71 (Pubitemid 35153452)
11. Erdei N, Papp Z, Pollesello P, Edes I, Bagi Z. The levosimendan metabolite OR-1896 elicits vasodilation by activating the K(ATP) and BK(Ca) channels in rat isolated arterioles. Br J Pharmacol 2006; 148: 696-702 (Pubitemid 43993060)
12. 2 con-sumption in dogs. Am J Physiol Heart Circ Physiol 2008; 294: H238-48
13. Andersen LW, Landow L, Baek L, Jansen E, Baker S. Association between gastric intramucosal pH and splanchnic endotoxin, anti-body to endotoxin, and tumor necrosis factor-alpha concen-trations in patients undergoing cardiopulmonary bypass. Crit Care Med 1993; 21: 210-7 (Pubitemid 23062834)
14. Koobi T, Kaukinen S, Turjanmaa VM, Uusitalo AJ. Whole-body impedance cardiography in the measurement of cardiac output. Crit Care Med 1997; 25: 779-85 (Pubitemid 27249154)
15. De Hert SG, Lorsomradee S, Cromheecke S, Van der Linden PJ. The effects of levosimendan in cardiac surgery patients with poor left ventricular function. Anesth Analg 2007; 104: 766-73 (Pubitemid 46548294)
16. Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion oflevo-simendan in patients with congestive heart failure. Eur J Heart Fail 2007; 9: 75-82 (Pubitemid 46074480)
17. Eriksson HI, Jalonen JR, Heikkinen LO, et al. Levosimendan facili-tates weaning from cardiopulmonary bypass in patients under-going coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg 2009; 87: 448-54
18. Kloner RA, Przyklenk K, Kay GL. Clinical evidence for stunned myo-cardium after coronary artery bypass surgery. J Card Surg 1994; 9: 397-402 (Pubitemid 24171173)
19. De Luca L, Sardella G, Proietti P, et al. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardio-graphic study. J Am Soc Echocardiogr 2006; 19: 172-7 (Pubitemid 43187160)
20. Zangrillo A, Biondi-Zoccai G, Mizzi A, et al. Levosimendan reduces cardiac troponin release after cardiac surgery: a meta-analysis of randomized controlled studies. J Cardiothorac Vasc Anesth 2009; 23: 474-478
21. Tasouli A, Papadopoulos K, Antoniou T, et al. Efficacy and safety of perioperative infusion oflevosimendan in patients with compro-mised cardiac function undergoing open-heart surgery: impor-tance of early use. Eur J Cardiothorac Surg 2007; 32: 629-33 (Pubitemid 47362731)
22. Kaukinen S, Koobi T, Bi Y, Turjanmaa VM. Cardiac output measure-ment after coronary artery bypass grafting using bolus thermodi-lution, continuous thermodilution, and whole-body impedance cardiography. J Cardiothorac Vasc Anesth 2003; 17: 199-203 (Pubitemid 36457475)
23. Koobi T, Kaukinen S, Turjanmaa VM. Cardiac output can be reliably measured noninvasively after coronary artery bypass grafting operation. Crit Care Med 1999; 27: 2206-11 (Pubitemid 29508339)
24. Koobi T, Kaukinen S, Ahola T, Turjanmaa VM. Non-invasive measurement of cardiac output: whole-body impedance cardio-graphy in simultaneous comparison with thermodilution and direct oxygen Fickmethods. Intensive Care Med 1997; 23:1132-7 (Pubitemid 27517319)
25. Widdowson EM, Dickerson JWT. Chemical composition of the body. In: Comar CI, Bronner F, eds. Mineral Metabolism: An Advanced Treatise. Vol II, The Elements, Part A. New York: Academic Press, 1964; 12-3
26. Kolesnikov IS, Lytkin MI, Tishchenko MI, Shanin IN, Volkov IN. Total-body rheography in surgical diseases of the chest organs (in Russian). Vestnik Khirurgii 1981; 126: 114-21
27. Kersten JR, Montgomery MW, Pagel PS, Warltier DC Levosimen-dan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 2000; 90: 5-11 (Pubitemid 30022959)
28. Tritapepe L, De Santis V, Vitale D, et al. Preconditioning effects of levosimendan in coronary artery bypass grafting\a pilot study. Br J Anaesth 2006; 96: 694-700 (Pubitemid 43786683)
29. de Ruijter W, Musters RJ, Boer C, Stienen GJ, Simonides WS, de Lange JJ. The cardioprotective effect of sevoflurane depends on protein kinase C activation, opening of mitochondrial K(+)(ATP) channels, and the production of reactive oxygen species. Anesth Analg 2003; 97: 1370-6 (Pubitemid 37310136)